Business
Jun 05, 2026
'Golden Years': Changing the story of ATTR-CMATTR-cardiac amyloidosis (ATTR-CM) is a progressive heart condition often mistaken for normal aging. For years,…
Jun 03, 2026
IntroductionAccording to Mordor Intelligence, the transthyretin amyloidosis treatment market size is expected to reach USD 7.05 billion in 2026 and is forecast to…
Jun 02, 2026
AccurKardia Granted Patent for AI-Driven ECG Detection of Cardiac AmyloidosisPatent establishes IP across all major amyloidosis subtypes and transforms the standard…
May 29, 2026
Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug…
May 28, 2026
The Key Hereditary Transthyretin Amyloidosis Companies in the market include - Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia…
May 21, 2026
At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…
May 14, 2026
Position: The Development Manager for the Amyloidosis Research Consortium (ARC) will be responsible for managing the full lifecycle of donor data, from initial…
May 13, 2026
At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…
May 12, 2026
Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.BridgeBio’s…
May 07, 2026
BridgeBio Pharma reports first-quarter earnings after the market close Thursday, with investors focused on the commercial trajectory of Attruby, the company’s…